首页 | 本学科首页   官方微博 | 高级检索  
     

TERT启动子突变在甲状腺癌中的研究进展
引用本文:唐新月,石 峰,黎翠林,刘剑秋,李 智.TERT启动子突变在甲状腺癌中的研究进展[J].金属学报,2017,22(3):350-354.
作者姓名:唐新月  石 峰  黎翠林  刘剑秋  李 智
作者单位:1. 中南大学湘雅医院临床药理研究所,长沙 410008,湖南; ;2.中南大学临床药理研究所,遗传药理学湖南省重点实验室,长沙 410078,湖南;;3. 湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院,长沙 410006,湖南
基金项目:国家新药创制重大专项(2012ZX09303013-004);湖南省高校创新平台开放基金项目(13K002)
摘    要:

关 键 词:甲状腺癌  端粒酶逆转录酶  启动子突变  
收稿时间:2016-11-09
修稿时间:2016-12-22

Research progress of TERT promoter mutation in thyroid cancer
TANG Xinyue,SHI Feng,LI Cuilin,LIU Jianqiu,LI Zhi.Research progress of TERT promoter mutation in thyroid cancer[J].Acta Metallurgica Sinica,2017,22(3):350-354.
Authors:TANG Xinyue  SHI Feng  LI Cuilin  LIU Jianqiu  LI Zhi
Affiliation:1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008,Hunan, China;2.Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, China;3. Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410006, Hunan, China
Abstract:Thyroid cancer is a common endocrine malignancy and its morbidity raised rapidly in recent years. The association between TERT promoter mutations (C228T,C250T) and clinical outcomes have been investigated since they were confirmed in thyroid cancer (including differentiated thyroid cancer and anaplastic thyroid cancer) in 2013. Most studies suggest the mutations are associated with thyroid cancer, the clinical outcomes and poor prognosis. The two mutations are considered to be oncogenic mutations. In order to provide a new sight into the research of TERT promoter mutation, diagnosis and treatment of thyroid cancer, we summarized the incidence of TERT promoter mutation in different types of thyroid cancer and the clinical relevance of these mutations.
Keywords:
点击此处可从《金属学报》浏览原始摘要信息
点击此处可从《金属学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号